152results about How to "Suppress immune response" patented technology

The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.

The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.

The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.

In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and / or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and / or or a pro-insulin therapeutic).

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and / or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and / or degraded within the GI tract.

A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanocparticle drug delivery system is also provided.

This invention provides methods for producing antibodies, wherein the methods comprise the step of administering an immunogen comprising both a target antigen and a background antigen to transgenic animals, into which a gene coding for the background antigen has been introduced. Since immunotolerance to the background antigens have thus been induced in the transgenic animals, the animals efficiently produce antibodies to target antigens.

A unique method and coatings are provided to promote / allow early stage tissue encapsulation / endothelization of medical devices while effectively controlling excessive tissue buildup by eluting antiproliferative therapeutic agent within a body of a patient. The method involves using a therapeutic agent that suppresses excessive extracellular matrix proliferation and allows / promotes thin tissue healing / encapsulation / endothelization of the device. Optimized timing of onset of elution to match onset of excessive extracellular matrix proliferation for maximum effectiveness is achieved by delay barrier with biochemical switch.

The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and / or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.

Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

The invention relates to mesenchymal stem cell membrane-coated bionic nanoparticles with overexpressed PD-L1 molecules on the surface as well as preparation and application of the mesenchymal stem cell membrane-coated bionic nanoparticles. The mesenchymal stem cell membrane-coated bionic nanoparticle with the overexpressed PD-L1 molecules on the surface comprises a nano-core and a mesenchymal stemcell membrane wrapping the nano-core, the nano core comprises a polymer with biocompatibility, and PD-L1 molecules are overexpressed on the membrane surface of the mesenchymal stem cell membrane. Theinvention also discloses an application of the mesenchymal stem cell membrane-coated bionic nano-particle with over-expressed PD-L1 molecules on the surface in preparation of an inflammation treatment preparation. The bionic nanoparticle has a remarkable immunosuppression effect, is high in biocompatibility and simple and mature in preparation process, can be used for preparing an inflammation treatment preparation, can be effectively enriched in an inflammation part, and shows an excellent curative effect in inflammation treatment by inhibiting excessively activated immune response and cytokine storm of the inflammation part.

A method of suppressing immune responses, comprising administering to a patient in need thereof an effective amount of a composition comprising a substance capable of reducing the content of reductive glutathione in macrophages.